(RTTNews) - Assembly Biosciences, Inc. (ASMB), a biotechnology company, Thursday announced encouraging interim data from Phase 1b study of ABI-4334 in participants with chronic hepatitis B virus infection.

Results from the first cohort of the Phase 1b study showed strong antiviral activity in participants who were treated with 150 mg dose of ABI-4334, a next-generation capsid assembly modulator (CAM). Further, the drug candidate was well tolerated with a favorable safety profile.

Enrollment is underway for the second and final cohort, evaluating 400 mg dose of ABI-4334 with data expected in the first half of 2025.

Under the collaboration agreement between Assembly Bio and Gilead Sciences, Inc., Gilead has the right to opt in to further development and commercialization for ABI-4334 after Assembly Bio's delivery of a data package following completion of this Phase 1b study, the company noted.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.